about
Crystal structure of the HIV-1 integrase core domain in complex with sucrose reveals details of an allosteric inhibitory binding siteFragment-based design of ligands targeting a novel site on the integrase enzyme of human immunodeficiency virus 1Parallel screening of low molecular weight fragment libraries: do differences in methodology affect hit identification?Structure-Activity Studies of β-Hairpin Peptide Inhibitors of the Plasmodium falciparum AMA1-RON2 Interaction2-aminothienopyridazines as novel adenosine A1 receptor allosteric modulators and antagonists.Determination of ligand binding modes in weak protein-ligand complexes using sparse NMR data.Computational Models of the Gastrointestinal Environment. 1. The Effect of Digestion on the Phase Behavior of Intestinal Fluids.A chemogenomic analysis of ionization constants--implications for drug discoveryHomology modeling of human muscarinic acetylcholine receptors.Design, Synthesis, and Biological Evaluation of Tetra-Substituted Thiophenes as Inhibitors of p38α MAPK.Thiazolidinedione-based PI3Kα inhibitors: an analysis of biochemical and virtual screening methods.Identification of mechanistically distinct inhibitors of HIV-1 reverse transcriptase through fragment screening.Fragment Based Strategies for Discovery of Novel HIV-1 Reverse Transcriptase and Integrase Inhibitors.Synthesis and Pharmacological Evaluation of 4-Iminothiazolidinones for Inhibition of PI3 KinaseThe significance of acid/base properties in drug discoveryDesign, Synthesis, and Characterization of Cyclic Peptidomimetics of the Inducible Nitric Oxide Synthase Binding Epitope That Disrupt the Protein-Protein Interaction Involving SPRY Domain-Containing Suppressor of Cytokine Signaling Box Protein (SPSBRedox-stable cyclic peptide inhibitors of the SPSB2-iNOS interaction.Free Energy Methods in Drug Design: Prospects of "Alchemical Perturbation" in Medicinal Chemistry.The Acid/Base Profile of the Human Metabolome and Natural Products.How kanamycin A interacts with bacterial and mammalian mimetic membranes.Homology modeling and docking evaluation of aminergic G protein-coupled receptors.Backbone and side chain 1H, 15N and 13C assignments for the oxidised and reduced forms of the oxidoreductase protein DsbA from Staphylococcus aureus.Probing the fibrate binding specificity of rat liver fatty acid binding protein.An orally bioavailable oxime ether capsid binder with potent activity against human rhinovirus.Digestion of phospholipids after secretion of bile into the duodenum changes the phase behavior of bile components.(+)-Fluorenylethylchloroformate (FLEC)--improved synthesis for application in chiral analysis and peptidomimetic synthesis.A three-dimensional model of the human immunodeficiency virus type 1 integration complex.Structure and dynamics of glyceride lipid formulations, with propylene glycol and water.Glyceride lipid formulations: molecular dynamics modeling of phase behavior during dispersion and molecular interactions between drugs and excipients.Computational Models of the Intestinal Environment. 3. The Impact of Cholesterol Content and pH on Mixed Micelle Colloids.2-Ethoxybenzoxazole as a bioisosteric replacement of an ethyl benzoate group in a human rhinovirus (HRV) capsid binder.Quantum chemical study of the intermediate complex required for iron-mediated reactivity and antimalarial activity of dispiro-1,2,4-trioxolanes.Computational Models of the Gastrointestinal Environment. 2. Phase Behavior and Drug Solubilization Capacity of a Type I Lipid-Based Drug Formulation after Digestion.The binding interaction of synthetic ozonide antimalarials with natural and modified beta-cyclodextrins.Beta amino acid-modified and fluorescently labelled kisspeptin analogues with potent KISS1R activity.Structure and activity of contryphan-Vc2: Importance of the d-amino acid residue.Polymeric Precipitation Inhibitors Promote Fenofibrate Supersaturation and Enhance Drug Absorption from a Type IV Lipid-Based Formulation.Ligand Binding Pathways of Clozapine and Haloperidol in the Dopamine D2 and D3 Receptors.Parallel and antiparallel cyclic d/l peptide nanotubes.Propargyloxyproline Regio- and Stereoisomers for Click-Conjugation of Peptides: Synthesis and Application in Linear and Cyclic Peptides
P50
Q27660224-84089FE4-3203-45BE-96AE-5F2D53180F14Q27666603-2A63F27D-2411-4316-AE6C-6E9F74B85422Q27683344-61863AE4-22EE-432E-A462-3D38EB9F2C58Q27719709-D82E130B-9FBF-4BB2-9743-4EA1C10B3472Q30439856-134E4449-12FB-415E-8F3A-CA38D645E232Q31138858-17C42ECC-C917-4BF0-971C-7CE3596C6E4EQ31155222-A477BB0F-94E0-4CA5-94AA-FD96B7CC57F6Q34543267-E80A2CDF-6031-4D38-BA82-EE42A2C63F81Q35064807-F6D78EF2-2B65-469B-8C13-05CFD0CC6B48Q35236755-BF97C32D-D508-4BA9-AD89-CDD73F6BDFACQ35276540-C37A54F5-F30C-4DB7-961A-95FF6B2AB235Q35650700-071FA117-864A-4C83-874B-01A5A886ED81Q35760683-7BD6C52E-2176-41BF-8511-CE485D77383BQ37127106-EE14B698-C2DE-4A33-8A63-0E0764E55DDDQ38055676-35DD7C99-7047-4787-821D-D220B187D76CQ38863737-6107987A-4995-4660-A90E-62AF01E8CDCAQ38902586-24994BC2-B09A-4CCA-8A74-1EA1839235F3Q39459175-7E3C740A-3279-43B1-81FC-7A4FB4DA06D2Q39535327-56237EFA-A48D-40AF-8369-CFCB4EF4E96EQ40067655-7F2E3531-64C1-4F6F-A7DC-6969410BCD5EQ43148221-4A0CC599-A4A9-40FF-AAC2-E5F50C196D7DQ43236084-8C8D186F-42C4-4D43-9EF7-417EFF71CE31Q43296520-AD4D5D9F-0658-4094-A2DF-8C8823A84201Q43617763-E3C4D97C-5A87-4024-BD4A-D21866D0F568Q45188967-7D292BE7-8976-4AD3-B158-34A60F062A19Q45375223-44054F0A-0099-47B6-AB7E-249A36DF9998Q45423719-ADD6BAB1-3071-4BBE-9D1B-B3226FB099E7Q46100753-0E56F7A4-0186-45A3-805C-59B0AD9F5B50Q46237310-8FE908D9-B57E-4F30-BB74-82AA67A3BD23Q46294226-DD8AC904-0F69-44E6-81A0-BBC9C78D41A4Q46420292-B933DEE2-66EF-429E-BEE2-18DBB4B7CB2DQ46436104-FF1F3706-5AFC-49DB-A15C-86893810CFCCQ46448008-ED617CC8-F935-4765-A56B-9C18E6E11BD5Q46825685-CEAF171F-F90A-4E97-BFDF-E4D5FB71E800Q48686268-F143004D-8995-4FBA-AD01-F2755F744A88Q51131197-9BA8CE01-9818-4CC5-831B-D776AA335B23Q52586282-317BF807-9BED-41C6-B07E-FE13421016C7Q53241398-35D33BCE-167E-4C5C-8E66-081DF5157483Q54273937-74E0AA8A-DB47-43D6-8790-9453F4899E24Q57835906-6DFBF1AD-8123-497C-984B-DD02754CEC11
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
David K. Chalmers
@ast
David K. Chalmers
@en
David K. Chalmers
@es
David K. Chalmers
@nl
David K. Chalmers
@sl
type
label
David K. Chalmers
@ast
David K. Chalmers
@en
David K. Chalmers
@es
David K. Chalmers
@nl
David K. Chalmers
@sl
prefLabel
David K. Chalmers
@ast
David K. Chalmers
@en
David K. Chalmers
@es
David K. Chalmers
@nl
David K. Chalmers
@sl
P1053
L-8533-2013
P106
P1153
7102932131
P21
P31
P3829
P496
0000-0003-2366-569X